A COMMITTED GLOBAL LEADER IN PSORIASIS RESEARCH

Zymbilan® is committed to increasing treatment results for all patients suffering from psoriasis.

Following the clinical establishment that the treatment of both hypoactive retinoid signalling and Epidermal Dysglycania (EDG) can reduce psoriasis symptoms, the primary focus of our research focuses on helping sufferers achieve epidermal homeostasis through:

1) clinically validated and proven retinoid therapies
2) research into the evolving importance of Proteoglycan Replacement Therapy in treating skin disorders.

Zymbilan® is a natural and drug-free therapy based on more than 70 scientific studies and clinical papers published in leading peer-review journals, some of which can be referenced below.

 

 

Clinical assessment of therapeutic effects of 4 weeks of monotherapy with Zymbilan®-PSO cream on psoriatic skin lesions rated by the participants (A) and a dermatologist (B).
Zymbilan®-PSO cream with nano-encapsulated RetileX-A®-PRO mitigates the clinical severity and relieves the symptoms of chronic plaque psoriasis: an interventional clinical study
45 patients (58% female, aged 18-80 years) with mild to moderate skin psoriasis were enrolled in a 4-week interventional study. Participants were treated once daily with Zymbilan®-PSO cream with RetileX-A®-PRO and evaluated both objectively and subjectively at baseline, after 8 hours and at endpoint. Our observations demonstrated that Zymbilan®-PSO cream possesses both short-term and long-term anti-psoriatic effects. Shortly after application, objective skin characteristics were improved, and itching reduced in >84% of subjects. At endpoint, 87% of skin lesions improved, 9% did not change and 4% progressed as assessed by a dermatologist. Patients’ self-evaluation yielded similar results: 78% judged Zymbilan®-PSO cream as a ‘good’ to ‘very good’ skin care product with suitable cosmetic parameters. No side effects were recorded in 95% of participants.

Conclusion: Based on our clinical observations in this study, Zymbilan®-PSO cream with nano-encapsulated RetileX- A®-PRO provides short-term symptomatic relief as well as long-term clinical improvement in patients with mild to moderate skin psoriasis. Treated patients reported substantial relief in skin itching and skin quality within a few hours after applying the product. Visible clinical improvement in the severity and size of skin lesions was noted after 4 weeks by patients and during dermatological examination. Common irritating side effects of topical retinoids were not observed with RetileX-A®-PRO in this study. Accordingly, we conclude that Zymbilan®-PSO cream is a safe and effective therapy that can be used in clinic as a first line measure against mild to moderate skin psoriasis as a monotherapy or in combination with other topical or systemic treatments.

Selected published clinical studies

Zymbilan®-PSO cream is a well-tolerated treatment that can mitigate both clinical severity and subjective symptoms of chronic skin psoriasis.

Icons

© Zymbilan®. ALL RIGHTS RESERVED. Zymbilan® is a brand from Pharma Medico.
Read the Zymbilan.com Terms & Conditions and Privacy Policy.